Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagonist

Executive Summary: Dantrolene sodium salt (SKU B6329, APExBIO) is a potent antagonist of ryanodine receptor (RyR) channels with an IC50 of 5.9 ± 0.3 nM for RyR2, enabling precision modulation of intracellular calcium release in diverse research workflows (product_spec). The compound acts in a calmodulin-dependent manner, restricting RyR activity only when calmodulin is present (Kobayashi et al., 2005, PubMed). Dantrolene has demonstrated efficacy in reducing cellular damage in mouse models of pancreatitis and is validated for short-term DMSO-based applications in cell and tissue studies (product_spec). Recent drug-repurposing screens highlight its utility in modulating DNA repair pathway choice during CRISPR genome editing (Nature Communications). This article integrates mechanistic, experimental, and product-specific data to inform optimal use and clarify boundaries for Dantrolene sodium salt in translational research.

Biological Rationale

Ryanodine receptors (RyRs) are calcium release channels located on the membranes of the endoplasmic and sarcoplasmic reticulum, essential for intracellular calcium homeostasis (review). Dysregulation of RyR-mediated calcium signaling contributes to pathophysiological states including ischemia, hypoxia, seizures, anesthesia-related complications, and neurodegenerative diseases (internal). Dantrolene sodium salt, as a selective RyR antagonist, enables researchers to dissect calcium-dependent processes, improving model fidelity in disease and gene-editing studies (internal). This mechanistic specificity is crucial for reproducibility in translational workflows.

Mechanism of Action of Dantrolene, sodium salt

Dantrolene sodium salt exhibits high affinity for RyR channels, particularly RyR2, with an IC50 of 5.9 ± 0.3 nM, as determined in purified mouse cardiac microsomes (product_spec). Its inhibitory effect is calmodulin-dependent, requiring the interaction of calmodulin with RyR for effective channel closure (Kobayashi et al., 2005, PubMed). In mouse cardiomyocytes, Dantrolene reduces both the frequency and amplitude of spontaneous calcium waves only in the presence of calmodulin. This targeted mechanism minimizes off-target effects on non-RyR calcium channels, distinguishing Dantrolene from less selective calcium signaling inhibitors (internal).

Evidence & Benchmarks

• Dantrolene sodium salt inhibits RyR2 with an IC50 of 5.9 ± 0.3 nM in mouse cardiac microsomes [source_type: product_spec] (source_link).
• Its inhibition of RyR is calmodulin-dependent, with no significant effect in the absence of calmodulin (Kobayashi et al., 2005, [source_type: paper], source_link).
• In vivo, Dantrolene reduces pancreatic trypsin activity and cellular damage in mouse models of caerulein-induced pancreatitis [source_type: paper] (source_link).
• In drug-repurposing screens, Dantrolene modulated DNA double-strand break (DSB) repair pathway choice in hiPSC CRISPR editing assays, affecting indel and HDR outcomes [source_type: paper] (source_link).
• Validated for solubility at ≥12.2 mg/mL in DMSO; insoluble in water and ethanol [source_type: product_spec] (source_link).
• Supplied at >98% purity with HPLC and NMR documentation [source_type: product_spec] (source_link).

This article expands on previous perspectives (see Targeting Ryanodine Receptor Signaling), offering detailed product-specific benchmarks and recent CRISPR data integration not covered in prior reviews.

Applications, Limits & Misconceptions

• Calcium Signaling Modulation: Dantrolene sodium salt is used to inhibit intracellular calcium release in cell, tissue, and organ models, supporting mechanistic studies in excitation-contraction coupling and calcium-dependent cell death (internal).
• Pancreatitis Research Compound: Its efficacy in reducing pancreatic enzyme activation and tissue damage has been validated in preclinical models (product_spec).
• Neurodegenerative Disease Model: Used to interrogate RyR-driven calcium dysregulation implicated in neurodegeneration (internal).
• CRISPR Workflow Optimization: Dantrolene's ability to modulate calcium-dependent DNA repair pathway outcomes supports its adoption in precise genome editing and synthetic lethality studies (Nature Communications).

Common Pitfalls or Misconceptions

• Not effective as a general calcium chelator; Dantrolene selectively targets RyR-mediated release, not all sources of cytosolic calcium [source_type: workflow_recommendation].
• Not suitable for long-term aqueous storage; Dantrolene solutions are recommended for short-term use only, preferably in DMSO [source_type: product_spec] (source_link).
• Activity is contingent on calmodulin presence; in calmodulin-deficient settings, RyR inhibition may be incomplete [source_type: paper] (source_link).
• Not broadly cytoprotective; efficacy is context-dependent and should not be assumed in all oxidative stress or apoptosis models [source_type: workflow_recommendation].
• No direct evidence for antiviral effects; use is not supported outside calcium signaling, DNA repair, or neurodegenerative research domains [source_type: workflow_recommendation].

For detailed protocol design and troubleshooting, refer to the authoritative guide Scenario-Driven Solutions for Dantrolene Sodium Salt, which outlines best practices for maximizing reproducibility—a key extension beyond the present mechanistic and benchmark-focused analysis.

Workflow Integration & Parameters

Protocol Parameters

• assay: RyR2 inhibition (IC50) | value_with_unit: 5.9 ± 0.3 nM | applicability: rodent cardiac microsomes | rationale: quantifies direct channel antagonism | source_type: product_spec (link)
• assay: Calcium wave suppression | value_with_unit: nM to µM range, calmodulin present | applicability: mouse cardiomyocytes | rationale: functional endpoint of RyR antagonism | source_type: paper (link)
• assay: Pancreatic trypsin activity | value_with_unit: significant reduction in vivo (dose-dependent, mg/kg) | applicability: mouse pancreatitis model | rationale: in vivo disease mitigation | source_type: product_spec (link)
• assay: Genome editing outcome modulation | value_with_unit: shifts in NHEJ/HDR/MMEJ proportions, see Fig. 1d | applicability: hiPSC CRISPR workflows | rationale: demonstrates cross-domain utility | source_type: paper (link)
• assay: Solubility | value_with_unit: ≥12.2 mg/mL in DMSO | applicability: stock preparation for cell/tissue assays | rationale: ensures experimental reproducibility | source_type: product_spec (link)
• assay: Storage | value_with_unit: room temperature (solid), short-term (solution) | applicability: lab handling | rationale: maintains stability and activity | source_type: product_spec (link)

This implementation guidance updates and clarifies earlier summaries (compare Advanced Ryanodine Receptor Antagonist, which focuses on potency and solubility, by incorporating CRISPR-specific outcomes and storage caveats.)

Conclusion & Outlook

Dantrolene sodium salt (APExBIO, B6329) stands as a benchmark ryanodine receptor antagonist for precision modulation of calcium signaling. Its nanomolar potency, calmodulin-dependent selectivity, and proven efficacy in both disease and gene-editing models underpin its value in translational research. Limitations include context-dependent activity and the necessity for calmodulin in target systems. Future research will build on recent findings that link calcium signaling modulation to DNA repair pathway choice, offering new avenues for synthetic lethality and genome editing optimization (Nature Communications). Ongoing integration of compound-specific benchmarks, workflow parameters, and stability data is essential for maximizing reproducibility and experimental clarity in advanced biomedical applications.